

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	10/525,115
Filing Date	August 31, 2005
First Named Inventor	Martin HENDRIX et al.
Art Unit	1624
Examiner Name	Jeffrey H. Murray
Attorney Docket Number	01-2112

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		5,977,118	11-02-1999	Bacon	
		5,656,629	08-12-1997	Bacon	
		5,002,949	03-26-1991	Peseckis	
		5,256,668	10-26-1993	Hsu	
		20060111372	05-25-2006	Hendrix	
		20060106035	05-18-2006	Hendrix	
		20040266736	12-30-2004	Wunder	
		20070161662	07-12-2007	Hendrix	
		20070105876	05-10-2007	Hendrix	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		CA 2 496 194	03-04-2004	Bayer Healthcare AG	This patent appears to be an English language equivalent to WO 2004/018474.	
		CA 2 496 292	04-01-2004	Bayer Healthcare AG	This patent appears to be an English language equivalent to WO2004/026286.	
		CA 2 496 308	04-01-2004	Bayer Healthcare AG	This patent appears to be an English language equivalent to WO2004/026876.	
		CA 2 438 890	09-06-2002	Bayer Aktiengesellschaft	This patent appears to be an English language equivalent to WO02/068423.	
		DE 1 156 415	10-31-1963	Ciba Limited		
		DE 101 56 249	05-28-2003	Bayer AG		
		DE 1 153 023	08-22-1963	Schmidt, et al.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(Use as many sheets as necessary)*

Sheet 2 of 4

Complete if Known

Application Number	10/525,115
Filing Date	August 31, 2005
First Named Inventor	Martin HENDRIX et al.
Art Unit	1624
Examiner Name	Jeffrey H. Murray
Attorney Docket Number	01-2112

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		EP 0 130 735	01-09-1985	American Home Products Corp.	.	
		EP 0 995 751	04-26-2000	Pfizer Inc.		
		GB 973361	10-28-1964	Ciba Limited		
		WO 02/055082	07-18-2002	Vernalis Research Limited		
		WO 03/037899	05-08-2003	Pfizer Limited		
		WO 03/93269	11-13-2003	Bayer Cropscience AG		
		WO 02/06288	01-24-2002	F. Hoffmann-la Roche AG		
		WO 95/10506	04-20-1995	The DuPont Pharmaceutical Co.		
		WO 00/18758	04-06-2000	Mitsubishi Chemical Corp.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(Use as many sheets as necessary)*

Sheet

3

of

4

Complete if Known

Application Number

10/525,115

Filing Date

August 31, 2005

First Named Inventor

Martin HENDRIX et al.

Art Unit

1624

Examiner Name

Jeffrey H. Murray

Attorney Docket Number

01-2112

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO 02/098864	12-12-2002	F. Hoffmann-La Roche AG	.	
		WO 99/41253	08-19-1999	Tularik Inc.		
		WO 98/10765	03-19-1998	The Board of Trustees of the Leland Stanford Junior University		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(Use as many sheets as necessary)*

Sheet 4 of 4

Complete if Known

Application Number	10/525,115
Filing Date	August 31, 2005
First Named Inventor	Martin HENDRIX, et al.
Art Unit	1624
Examiner Name	Jeffrey H. Murray
Attorney Docket Number	01-2112

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		FRANK WUNDER, ET AL; Characterization of the First Potent and Selective PDE9 Inhibitor Using a cGMP Reporter Cell Line; Molecular Pharmacology (2005) vol 68, no 6 pages 1775-1781.	
		MAGNUS ROENN, ET AL; Palladium (II)-Catalyzed Cyclization Using Molecular Oxygen as Reoxidant; Tetrahedron Letters (1995) vol. 36, no. 42, pp. 7749-7752.	
		HIEKE GIELEN, ET AL; A Novel Approach to Amidines from Esters; Tetrahedron Letters (2002) vol. 43 pages 419-421.	
		K. HEMENDER REDDY, ET AL; Versatile Synthesis of 6-Alkyl/Aryl-1H-Pyrazolo[3,4-d]Pyrimidin-4[5H]-Ones; Indian Journal of Chemistry (1992) vol. 31B, pages 163-166.	
		ARNE SCHOUSBOE, ET AL; Role of Ca++ and Other Second Messengers in Excitatory Amino Acid Receptor Mediated Neuogenesis: Clinical Perspective; Clinical Neuroscience (1997) vol. 4, pages 194-198.	
		CLAIRE LUGNIER; Cyclic Nucleotide Phosphodiesterase (PDE) Superfamily: A New Target for the Development of Specific Therapeutic Agents; Pharmacology & Therapeutics (2006) vol. 109 pages 366-398.	
		JEHAN BAGLI, ET AL; Chemistry and Positive Inotropic Effect of Pelrinone and related Derivates. A Novel Class of 2-Methylpyrimidones as Inotropic Agents; Journal of Medicinal Chemistry (1988) vol. 31 pages 814-823.	
		RUDOLF GOMPPER, ET AL; Substituted Dithiocarboxylic Acids and Ketene Thioacetals; Institute for Organic Chemistry Technology (1962) vol. 95, pages 2861-2870. German & English Translation.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.